Skip to content

Triangle Get started

← Full study record

NCT06055075 · OUTCOME

Serum Concentrations of Forimtamig at the Specified Timepoints

A Study Evaluating Safety, Tolerability, and Clinical Activity of Forimtamig-Based Treatment Combinations in Participants With Relapsed or Refractory Multiple Myeloma · Source last updated 2026-09-29

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure: GEOMETRIC_MEAN
Unit: nanograms per milliliter (ng/mL)
Interval / dispersion: Geometric Coefficient of Variation
Time frame: Pre-dose on Day (D)1 of Cycle (C)1,2&4, D4 of C1&5, D2C3; 4hours post-dose on D1,4 of C1, D2C3, D1C4, D4C5; D2,8,9,11,15,16&18 of C1; D2,8,15,22 of C2&4; D1,4,8,15,22 of C3; D1,8,15 of C5; D1,4,8,15 of C6,7,8&9; D1,4,8 of C10

Analysis population: Pharmacokinetic (PK)-evaluable population included all participants in the safety population who had PK data from at least one post-dose sample. Overall number analyzed is the number of participants with data available for analysis. Number analyzed is the number of participants with data available for analysis at the specified time points.

Groups in this outcome

Cohort 1: Arm B1: Forimtamig 0.3 mg + Carfilzomib

Participants received step-up doses of forimtamig 0.03 mg on Cycle 1 Day 1, 0.15 mg on Cycle 1 Day 8, and the target dose of 0.3 mg on Cycle 1 Day 15 and on Days 1 and 15 of each subsequent cycle, administered as a SC injection. Participants also received carfilzomib, 20 mg/m\^2 on Cycle 2 Day 1 and 56 mg/m\^2 on Cycle 2 Days 8 and 15, and from Cycle 3 onwards on Days 1, 8, and 15, administered as an IV infusion (1 cycle = 28 days).

Cohort 1: Arm B2: Forimtamig 0.75 mg + Carfilzomib

Participants received step-up doses of forimtamig, 0.03 mg on Cycle 1 Day 1, 0.15 mg on Cycle 1 Day 8, and the target dose of 0.75 mg on Cycle 1 Day 15 and on Days 1 and 15 of each subsequent cycle, administered as a SC injection. Participants also received carfilzomib 20 mg/m\^2 on Cycle 2 Day 1 and 56 mg/m\^2 on Cycle 2 Days 8 and 15, and from Cycle 3 onwards on Days 1, 8, and 15, administered as an IV infusion (1 cycle = 28 days).

Cohort 1: Arm B3: Forimtamig 1.5 mg + Carfilzomib

Participants received step-up doses of forimtamig, 0.03 mg on Cycle 1 Day 1, 0.15 mg on Cycle 1 Day 8, and the target dose of 1.5 mg on Cycle 1 Day 15 and on Days 1 and 15 of each subsequent cycle, administered as a SC injection. Participants also received carfilzomib, 20 mg/m\^2 on Cycle 2 Day 1 and 56 mg/m\^2 on Cycle 2 Days 8 and 15, and from Cycle 3 onwards on Days 1, 8, and 15, administered as an IV infusion (1 cycle = 28 days).

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

Group	Source count
Cohort 1: Arm B1: Forimtamig 0.3 mg + Carfilzomib	7
Cohort 1: Arm B2: Forimtamig 0.75 mg + Carfilzomib	6
Cohort 1: Arm B3: Forimtamig 1.5 mg + Carfilzomib	6

Reported measurements

Pre-dose Cycle 1 Day 1

Analysis denominator · Participants

Group	Source count
Cohort 1: Arm B1: Forimtamig 0.3 mg + Carfilzomib	7
Cohort 1: Arm B2: Forimtamig 0.75 mg + Carfilzomib	2
Cohort 1: Arm B3: Forimtamig 1.5 mg + Carfilzomib	4

Values in nanograms per milliliter (ng/mL) · Interval/dispersion: Geometric Coefficient of Variation
Group	Value	Spread	Lower	Upper	Comment
Cohort 1: Arm B1: Forimtamig 0.3 mg + Carfilzomib	NA	NA	Not reported	Not reported	Geometric mean and geometric coefficient of variation were not estimable as samples were below the limit of quantification (BLQ).
Cohort 1: Arm B2: Forimtamig 0.75 mg + Carfilzomib	NA	NA	Not reported	Not reported	Geometric mean and geometric coefficient of variation were not estimable as samples were BLQ.
Cohort 1: Arm B3: Forimtamig 1.5 mg + Carfilzomib	NA	NA	Not reported	Not reported	Geometric mean and geometric coefficient of variation were not estimable as samples were BLQ.

4hours Post-dose Cycle 1 Day 1

Analysis denominator · Participants

Group	Source count
Cohort 1: Arm B1: Forimtamig 0.3 mg + Carfilzomib	7
Cohort 1: Arm B2: Forimtamig 0.75 mg + Carfilzomib	2
Cohort 1: Arm B3: Forimtamig 1.5 mg + Carfilzomib	4

Values in nanograms per milliliter (ng/mL) · Interval/dispersion: Geometric Coefficient of Variation
Group	Value	Spread	Lower	Upper	Comment
Cohort 1: Arm B1: Forimtamig 0.3 mg + Carfilzomib	NA	NA	Not reported	Not reported	Geometric mean and geometric coefficient of variation were not estimable as samples were BLQ.
Cohort 1: Arm B2: Forimtamig 0.75 mg + Carfilzomib	NA	NA	Not reported	Not reported	Geometric mean and geometric coefficient of variation were not estimable as samples were BLQ.
Cohort 1: Arm B3: Forimtamig 1.5 mg + Carfilzomib	NA	NA	Not reported	Not reported	Geometric mean and geometric coefficient of variation were not estimable as samples were BLQ.

Cycle 1 Day 2

Analysis denominator · Participants

Group	Source count
Cohort 1: Arm B1: Forimtamig 0.3 mg + Carfilzomib	6
Cohort 1: Arm B2: Forimtamig 0.75 mg + Carfilzomib	5
Cohort 1: Arm B3: Forimtamig 1.5 mg + Carfilzomib	6

Values in nanograms per milliliter (ng/mL) · Interval/dispersion: Geometric Coefficient of Variation
Group	Value	Spread	Lower	Upper	Comment
Cohort 1: Arm B1: Forimtamig 0.3 mg + Carfilzomib	6.21	109.6	Not reported	Not reported	Not reported
Cohort 1: Arm B2: Forimtamig 0.75 mg + Carfilzomib	2.76	94.8	Not reported	Not reported	Not reported
Cohort 1: Arm B3: Forimtamig 1.5 mg + Carfilzomib	2.44	250.5	Not reported	Not reported	Not reported

Pre-dose Cycle 1 Day 4

Analysis denominator · Participants

Group	Source count
Cohort 1: Arm B1: Forimtamig 0.3 mg + Carfilzomib	6
Cohort 1: Arm B2: Forimtamig 0.75 mg + Carfilzomib	6
Cohort 1: Arm B3: Forimtamig 1.5 mg + Carfilzomib	6

Values in nanograms per milliliter (ng/mL) · Interval/dispersion: Geometric Coefficient of Variation
Group	Value	Spread	Lower	Upper	Comment
Cohort 1: Arm B1: Forimtamig 0.3 mg + Carfilzomib	6.55	50.8	Not reported	Not reported	Not reported
Cohort 1: Arm B2: Forimtamig 0.75 mg + Carfilzomib	3.69	115.3	Not reported	Not reported	Not reported
Cohort 1: Arm B3: Forimtamig 1.5 mg + Carfilzomib	2.64	384.1	Not reported	Not reported	Not reported

4 hours Post-dose Cycle 1 Day 4

Analysis denominator · Participants

Group	Source count
Cohort 1: Arm B1: Forimtamig 0.3 mg + Carfilzomib	5
Cohort 1: Arm B2: Forimtamig 0.75 mg + Carfilzomib	6
Cohort 1: Arm B3: Forimtamig 1.5 mg + Carfilzomib	6

Values in nanograms per milliliter (ng/mL) · Interval/dispersion: Geometric Coefficient of Variation
Group	Value	Spread	Lower	Upper	Comment
Cohort 1: Arm B1: Forimtamig 0.3 mg + Carfilzomib	7.26	52.4	Not reported	Not reported	Not reported
Cohort 1: Arm B2: Forimtamig 0.75 mg + Carfilzomib	6.99	69.9	Not reported	Not reported	Not reported
Cohort 1: Arm B3: Forimtamig 1.5 mg + Carfilzomib	NA	NA	Not reported	Not reported	Geometric mean and geometric coefficient of variation were not estimable as samples were BLQ.

Cycle 1 Day 8

Analysis denominator · Participants

Group	Source count
Cohort 1: Arm B1: Forimtamig 0.3 mg + Carfilzomib	5
Cohort 1: Arm B2: Forimtamig 0.75 mg + Carfilzomib	6
Cohort 1: Arm B3: Forimtamig 1.5 mg + Carfilzomib	6

Values in nanograms per milliliter (ng/mL) · Interval/dispersion: Geometric Coefficient of Variation
Group	Value	Spread	Lower	Upper	Comment
Cohort 1: Arm B1: Forimtamig 0.3 mg + Carfilzomib	10.3	44.7	Not reported	Not reported	Not reported
Cohort 1: Arm B2: Forimtamig 0.75 mg + Carfilzomib	21.4	51.6	Not reported	Not reported	Not reported
Cohort 1: Arm B3: Forimtamig 1.5 mg + Carfilzomib	25.4	434.0	Not reported	Not reported	Not reported

Cycle 1 Day 9

Analysis denominator · Participants

Group	Source count
Cohort 1: Arm B1: Forimtamig 0.3 mg + Carfilzomib	4
Cohort 1: Arm B2: Forimtamig 0.75 mg + Carfilzomib	6
Cohort 1: Arm B3: Forimtamig 1.5 mg + Carfilzomib	6

Values in nanograms per milliliter (ng/mL) · Interval/dispersion: Geometric Coefficient of Variation
Group	Value	Spread	Lower	Upper	Comment
Cohort 1: Arm B1: Forimtamig 0.3 mg + Carfilzomib	13.0	33.9	Not reported	Not reported	Not reported
Cohort 1: Arm B2: Forimtamig 0.75 mg + Carfilzomib	14.9	589.1	Not reported	Not reported	Not reported
Cohort 1: Arm B3: Forimtamig 1.5 mg + Carfilzomib	39.3	268.2	Not reported	Not reported	Not reported

Cycle 1 Day 11

Analysis denominator · Participants

Group	Source count
Cohort 1: Arm B1: Forimtamig 0.3 mg + Carfilzomib	7
Cohort 1: Arm B2: Forimtamig 0.75 mg + Carfilzomib	2
Cohort 1: Arm B3: Forimtamig 1.5 mg + Carfilzomib	4

Values in nanograms per milliliter (ng/mL) · Interval/dispersion: Geometric Coefficient of Variation
Group	Value	Spread	Lower	Upper	Comment
Cohort 1: Arm B1: Forimtamig 0.3 mg + Carfilzomib	NA	NA	Not reported	Not reported	Geometric mean and geometric coefficient of variation were not estimable as samples were BLQ.
Cohort 1: Arm B2: Forimtamig 0.75 mg + Carfilzomib	NA	NA	Not reported	Not reported	Geometric mean and geometric coefficient of variation were not estimable as samples were BLQ.
Cohort 1: Arm B3: Forimtamig 1.5 mg + Carfilzomib	NA	NA	Not reported	Not reported	Geometric mean and geometric coefficient of variation were not estimable as samples were BLQ.

Cycle 1 Day 15

Analysis denominator · Participants

Group	Source count
Cohort 1: Arm B1: Forimtamig 0.3 mg + Carfilzomib	7
Cohort 1: Arm B2: Forimtamig 0.75 mg + Carfilzomib	2
Cohort 1: Arm B3: Forimtamig 1.5 mg + Carfilzomib	4

Values in nanograms per milliliter (ng/mL) · Interval/dispersion: Geometric Coefficient of Variation
Group	Value	Spread	Lower	Upper	Comment
Cohort 1: Arm B1: Forimtamig 0.3 mg + Carfilzomib	NA	NA	Not reported	Not reported	Geometric mean and geometric coefficient of variation were not estimable as samples were BLQ.
Cohort 1: Arm B2: Forimtamig 0.75 mg + Carfilzomib	NA	NA	Not reported	Not reported	Geometric mean and geometric coefficient of variation were not estimable as samples were BLQ.
Cohort 1: Arm B3: Forimtamig 1.5 mg + Carfilzomib	0.367	100.8	Not reported	Not reported	Not reported

Cycle 1 Day 16

Analysis denominator · Participants

Group	Source count
Cohort 1: Arm B1: Forimtamig 0.3 mg + Carfilzomib	2
Cohort 1: Arm B2: Forimtamig 0.75 mg + Carfilzomib	1
Cohort 1: Arm B3: Forimtamig 1.5 mg + Carfilzomib	1

Values in nanograms per milliliter (ng/mL) · Interval/dispersion: Geometric Coefficient of Variation
Group	Value	Spread	Lower	Upper	Comment
Cohort 1: Arm B1: Forimtamig 0.3 mg + Carfilzomib	17.0	13.8	Not reported	Not reported	Not reported
Cohort 1: Arm B2: Forimtamig 0.75 mg + Carfilzomib	18.9	NA	Not reported	Not reported	Geometric coefficient of variation was not estimable for 1 participant.
Cohort 1: Arm B3: Forimtamig 1.5 mg + Carfilzomib	147	NA	Not reported	Not reported	Geometric coefficient of variation was not estimable for 1 participant.

Cycle 1 Day 18

Analysis denominator · Participants

Group	Source count
Cohort 1: Arm B1: Forimtamig 0.3 mg + Carfilzomib	2
Cohort 1: Arm B2: Forimtamig 0.75 mg + Carfilzomib	1
Cohort 1: Arm B3: Forimtamig 1.5 mg + Carfilzomib	1

Values in nanograms per milliliter (ng/mL) · Interval/dispersion: Geometric Coefficient of Variation
Group	Value	Spread	Lower	Upper	Comment
Cohort 1: Arm B1: Forimtamig 0.3 mg + Carfilzomib	23.2	0.6	Not reported	Not reported	Not reported
Cohort 1: Arm B2: Forimtamig 0.75 mg + Carfilzomib	27.7	NA	Not reported	Not reported	Geometric coefficient of variation was not estimable for 1 participant.
Cohort 1: Arm B3: Forimtamig 1.5 mg + Carfilzomib	178	NA	Not reported	Not reported	Geometric coefficient of variation was not estimable for 1 participant.

Pre-dose Cycle 2 Day 1

Analysis denominator · Participants

Group	Source count
Cohort 1: Arm B1: Forimtamig 0.3 mg + Carfilzomib	6
Cohort 1: Arm B2: Forimtamig 0.75 mg + Carfilzomib	6
Cohort 1: Arm B3: Forimtamig 1.5 mg + Carfilzomib	6

Values in nanograms per milliliter (ng/mL) · Interval/dispersion: Geometric Coefficient of Variation
Group	Value	Spread	Lower	Upper	Comment
Cohort 1: Arm B1: Forimtamig 0.3 mg + Carfilzomib	0.712	121.8	Not reported	Not reported	Not reported
Cohort 1: Arm B2: Forimtamig 0.75 mg + Carfilzomib	NA	NA	Not reported	Not reported	Geometric mean and geometric coefficient of variation were not estimable as samples were BLQ.
Cohort 1: Arm B3: Forimtamig 1.5 mg + Carfilzomib	NA	NA	Not reported	Not reported	Geometric mean and geometric coefficient of variation were not estimable as samples were BLQ.

4hours Post-dose Cycle 2 Day 1

Analysis denominator · Participants

Group	Source count
Cohort 1: Arm B1: Forimtamig 0.3 mg + Carfilzomib	6
Cohort 1: Arm B2: Forimtamig 0.75 mg + Carfilzomib	6
Cohort 1: Arm B3: Forimtamig 1.5 mg + Carfilzomib	6

Values in nanograms per milliliter (ng/mL) · Interval/dispersion: Geometric Coefficient of Variation
Group	Value	Spread	Lower	Upper	Comment
Cohort 1: Arm B1: Forimtamig 0.3 mg + Carfilzomib	2.08	98.1	Not reported	Not reported	Not reported
Cohort 1: Arm B2: Forimtamig 0.75 mg + Carfilzomib	0.363	120.4	Not reported	Not reported	Not reported
Cohort 1: Arm B3: Forimtamig 1.5 mg + Carfilzomib	NA	NA	Not reported	Not reported	Geometric mean and geometric coefficient of variation were not estimable as samples were BLQ.

Cycle 2 Day 2

Analysis denominator · Participants

Group	Source count
Cohort 1: Arm B1: Forimtamig 0.3 mg + Carfilzomib	6
Cohort 1: Arm B2: Forimtamig 0.75 mg + Carfilzomib	6
Cohort 1: Arm B3: Forimtamig 1.5 mg + Carfilzomib	6

Values in nanograms per milliliter (ng/mL) · Interval/dispersion: Geometric Coefficient of Variation
Group	Value	Spread	Lower	Upper	Comment
Cohort 1: Arm B1: Forimtamig 0.3 mg + Carfilzomib	3.89	157.2	Not reported	Not reported	Not reported
Cohort 1: Arm B2: Forimtamig 0.75 mg + Carfilzomib	1.36	83.4	Not reported	Not reported	Not reported
Cohort 1: Arm B3: Forimtamig 1.5 mg + Carfilzomib	1.57	321.8	Not reported	Not reported	Not reported

Cycle 2 Day 8

Analysis denominator · Participants

Group	Source count
Cohort 1: Arm B1: Forimtamig 0.3 mg + Carfilzomib	1
Cohort 1: Arm B2: Forimtamig 0.75 mg + Carfilzomib	1
Cohort 1: Arm B3: Forimtamig 1.5 mg + Carfilzomib	0

Values in nanograms per milliliter (ng/mL) · Interval/dispersion: Geometric Coefficient of Variation
Group	Value	Spread	Lower	Upper	Comment
Cohort 1: Arm B1: Forimtamig 0.3 mg + Carfilzomib	14.1	NA	Not reported	Not reported	Geometric coefficient of variation was not estimable for 1 participant.
Cohort 1: Arm B2: Forimtamig 0.75 mg + Carfilzomib	8.82	NA	Not reported	Not reported	Geometric coefficient of variation was not estimable for 1 participant.

Cycle 2 Day 15

Analysis denominator · Participants

Group	Source count
Cohort 1: Arm B1: Forimtamig 0.3 mg + Carfilzomib	1
Cohort 1: Arm B2: Forimtamig 0.75 mg + Carfilzomib	0
Cohort 1: Arm B3: Forimtamig 1.5 mg + Carfilzomib	0

Values in nanograms per milliliter (ng/mL) · Interval/dispersion: Geometric Coefficient of Variation
Group	Value	Spread	Lower	Upper	Comment
Cohort 1: Arm B1: Forimtamig 0.3 mg + Carfilzomib	23.8	NA	Not reported	Not reported	Geometric coefficient of variation was not estimable for 1 participant.

Cycle 2 Day 22

Analysis denominator · Participants

Group	Source count
Cohort 1: Arm B1: Forimtamig 0.3 mg + Carfilzomib	2
Cohort 1: Arm B2: Forimtamig 0.75 mg + Carfilzomib	1
Cohort 1: Arm B3: Forimtamig 1.5 mg + Carfilzomib	1

Values in nanograms per milliliter (ng/mL) · Interval/dispersion: Geometric Coefficient of Variation
Group	Value	Spread	Lower	Upper	Comment
Cohort 1: Arm B1: Forimtamig 0.3 mg + Carfilzomib	29.4	34.5	Not reported	Not reported	Not reported
Cohort 1: Arm B2: Forimtamig 0.75 mg + Carfilzomib	38.6	NA	Not reported	Not reported	Geometric coefficient of variation was not estimable for 1 participant.
Cohort 1: Arm B3: Forimtamig 1.5 mg + Carfilzomib	212	NA	Not reported	Not reported	Geometric coefficient of variation was not estimable for 1 participant.

Cycle 3 Day 1

Analysis denominator · Participants

Group	Source count
Cohort 1: Arm B1: Forimtamig 0.3 mg + Carfilzomib	1
Cohort 1: Arm B2: Forimtamig 0.75 mg + Carfilzomib	1
Cohort 1: Arm B3: Forimtamig 1.5 mg + Carfilzomib	0

Values in nanograms per milliliter (ng/mL) · Interval/dispersion: Geometric Coefficient of Variation
Group	Value	Spread	Lower	Upper	Comment
Cohort 1: Arm B1: Forimtamig 0.3 mg + Carfilzomib	26.0	NA	Not reported	Not reported	Geometric coefficient of variation was not estimable for 1 participant.
Cohort 1: Arm B2: Forimtamig 0.75 mg + Carfilzomib	28.1	NA	Not reported	Not reported	Geometric coefficient of variation was not estimable for 1 participant.

Pre-dose Cycle 3 Day 2

Analysis denominator · Participants

Group	Source count
Cohort 1: Arm B1: Forimtamig 0.3 mg + Carfilzomib	6
Cohort 1: Arm B2: Forimtamig 0.75 mg + Carfilzomib	5
Cohort 1: Arm B3: Forimtamig 1.5 mg + Carfilzomib	6

Values in nanograms per milliliter (ng/mL) · Interval/dispersion: Geometric Coefficient of Variation
Group	Value	Spread	Lower	Upper	Comment
Cohort 1: Arm B1: Forimtamig 0.3 mg + Carfilzomib	10.6	72.2	Not reported	Not reported	Not reported
Cohort 1: Arm B2: Forimtamig 0.75 mg + Carfilzomib	25.6	74.1	Not reported	Not reported	Not reported
Cohort 1: Arm B3: Forimtamig 1.5 mg + Carfilzomib	11.8	379.4	Not reported	Not reported	Not reported

4hours Post-dose Cycle 3 Day 2

Analysis denominator · Participants

Group	Source count
Cohort 1: Arm B1: Forimtamig 0.3 mg + Carfilzomib	4
Cohort 1: Arm B2: Forimtamig 0.75 mg + Carfilzomib	4
Cohort 1: Arm B3: Forimtamig 1.5 mg + Carfilzomib	5

Values in nanograms per milliliter (ng/mL) · Interval/dispersion: Geometric Coefficient of Variation
Group	Value	Spread	Lower	Upper	Comment
Cohort 1: Arm B1: Forimtamig 0.3 mg + Carfilzomib	11.9	61.2	Not reported	Not reported	Not reported
Cohort 1: Arm B2: Forimtamig 0.75 mg + Carfilzomib	27.9	97.7	Not reported	Not reported	Not reported
Cohort 1: Arm B3: Forimtamig 1.5 mg + Carfilzomib	10.2	344.1	Not reported	Not reported	Not reported

Cycle 3 Day 4

Analysis denominator · Participants

Group	Source count
Cohort 1: Arm B1: Forimtamig 0.3 mg + Carfilzomib	6
Cohort 1: Arm B2: Forimtamig 0.75 mg + Carfilzomib	6
Cohort 1: Arm B3: Forimtamig 1.5 mg + Carfilzomib	5

Values in nanograms per milliliter (ng/mL) · Interval/dispersion: Geometric Coefficient of Variation
Group	Value	Spread	Lower	Upper	Comment
Cohort 1: Arm B1: Forimtamig 0.3 mg + Carfilzomib	11.5	61.3	Not reported	Not reported	Not reported
Cohort 1: Arm B2: Forimtamig 0.75 mg + Carfilzomib	20.0	109.7	Not reported	Not reported	Not reported
Cohort 1: Arm B3: Forimtamig 1.5 mg + Carfilzomib	23.0	319.2	Not reported	Not reported	Not reported

Cycle 3 Day 8

Analysis denominator · Participants

Group	Source count
Cohort 1: Arm B1: Forimtamig 0.3 mg + Carfilzomib	4
Cohort 1: Arm B2: Forimtamig 0.75 mg + Carfilzomib	4
Cohort 1: Arm B3: Forimtamig 1.5 mg + Carfilzomib	4

Values in nanograms per milliliter (ng/mL) · Interval/dispersion: Geometric Coefficient of Variation
Group	Value	Spread	Lower	Upper	Comment
Cohort 1: Arm B1: Forimtamig 0.3 mg + Carfilzomib	16.1	88.8	Not reported	Not reported	Not reported
Cohort 1: Arm B2: Forimtamig 0.75 mg + Carfilzomib	35.0	114.6	Not reported	Not reported	Not reported
Cohort 1: Arm B3: Forimtamig 1.5 mg + Carfilzomib	25.0	293.4	Not reported	Not reported	Not reported

Cycle 3 Day 15

Analysis denominator · Participants

Group	Source count
Cohort 1: Arm B1: Forimtamig 0.3 mg + Carfilzomib	5
Cohort 1: Arm B2: Forimtamig 0.75 mg + Carfilzomib	5
Cohort 1: Arm B3: Forimtamig 1.5 mg + Carfilzomib	5

Values in nanograms per milliliter (ng/mL) · Interval/dispersion: Geometric Coefficient of Variation
Group	Value	Spread	Lower	Upper	Comment
Cohort 1: Arm B1: Forimtamig 0.3 mg + Carfilzomib	19.2	48.3	Not reported	Not reported	Not reported
Cohort 1: Arm B2: Forimtamig 0.75 mg + Carfilzomib	67.4	60.5	Not reported	Not reported	Not reported
Cohort 1: Arm B3: Forimtamig 1.5 mg + Carfilzomib	43.7	378.9	Not reported	Not reported	Not reported

Cycle 3 Day 22

Analysis denominator · Participants

Group	Source count
Cohort 1: Arm B1: Forimtamig 0.3 mg + Carfilzomib	5
Cohort 1: Arm B2: Forimtamig 0.75 mg + Carfilzomib	4
Cohort 1: Arm B3: Forimtamig 1.5 mg + Carfilzomib	4

Values in nanograms per milliliter (ng/mL) · Interval/dispersion: Geometric Coefficient of Variation
Group	Value	Spread	Lower	Upper	Comment
Cohort 1: Arm B1: Forimtamig 0.3 mg + Carfilzomib	19.2	69.4	Not reported	Not reported	Not reported
Cohort 1: Arm B2: Forimtamig 0.75 mg + Carfilzomib	54.2	53.0	Not reported	Not reported	Not reported
Cohort 1: Arm B3: Forimtamig 1.5 mg + Carfilzomib	32.9	446.0	Not reported	Not reported	Not reported

Pre-dose Cycle 4 Day 1

Analysis denominator · Participants

Group	Source count
Cohort 1: Arm B1: Forimtamig 0.3 mg + Carfilzomib	6
Cohort 1: Arm B2: Forimtamig 0.75 mg + Carfilzomib	5
Cohort 1: Arm B3: Forimtamig 1.5 mg + Carfilzomib	6

Values in nanograms per milliliter (ng/mL) · Interval/dispersion: Geometric Coefficient of Variation
Group	Value	Spread	Lower	Upper	Comment
Cohort 1: Arm B1: Forimtamig 0.3 mg + Carfilzomib	13.1	29.6	Not reported	Not reported	Not reported
Cohort 1: Arm B2: Forimtamig 0.75 mg + Carfilzomib	28.4	44.6	Not reported	Not reported	Not reported
Cohort 1: Arm B3: Forimtamig 1.5 mg + Carfilzomib	24.0	401.5	Not reported	Not reported	Not reported

4hours Post-dose Cycle 4 Day 1

Analysis denominator · Participants

Group	Source count
Cohort 1: Arm B1: Forimtamig 0.3 mg + Carfilzomib	6
Cohort 1: Arm B2: Forimtamig 0.75 mg + Carfilzomib	3
Cohort 1: Arm B3: Forimtamig 1.5 mg + Carfilzomib	4

Values in nanograms per milliliter (ng/mL) · Interval/dispersion: Geometric Coefficient of Variation
Group	Value	Spread	Lower	Upper	Comment
Cohort 1: Arm B1: Forimtamig 0.3 mg + Carfilzomib	14.8	37.9	Not reported	Not reported	Not reported
Cohort 1: Arm B2: Forimtamig 0.75 mg + Carfilzomib	26.9	56.9	Not reported	Not reported	Not reported
Cohort 1: Arm B3: Forimtamig 1.5 mg + Carfilzomib	44.3	273.3	Not reported	Not reported	Not reported

Cycle 4 Day 2

Analysis denominator · Participants

Group	Source count
Cohort 1: Arm B1: Forimtamig 0.3 mg + Carfilzomib	6
Cohort 1: Arm B2: Forimtamig 0.75 mg + Carfilzomib	5
Cohort 1: Arm B3: Forimtamig 1.5 mg + Carfilzomib	4

Values in nanograms per milliliter (ng/mL) · Interval/dispersion: Geometric Coefficient of Variation
Group	Value	Spread	Lower	Upper	Comment
Cohort 1: Arm B1: Forimtamig 0.3 mg + Carfilzomib	17.4	29.3	Not reported	Not reported	Not reported
Cohort 1: Arm B2: Forimtamig 0.75 mg + Carfilzomib	27.9	152.3	Not reported	Not reported	Not reported
Cohort 1: Arm B3: Forimtamig 1.5 mg + Carfilzomib	42.9	220.0	Not reported	Not reported	Not reported

Cycle 4 Day 8

Analysis denominator · Participants

Group	Source count
Cohort 1: Arm B1: Forimtamig 0.3 mg + Carfilzomib	6
Cohort 1: Arm B2: Forimtamig 0.75 mg + Carfilzomib	5
Cohort 1: Arm B3: Forimtamig 1.5 mg + Carfilzomib	2

Values in nanograms per milliliter (ng/mL) · Interval/dispersion: Geometric Coefficient of Variation
Group	Value	Spread	Lower	Upper	Comment
Cohort 1: Arm B1: Forimtamig 0.3 mg + Carfilzomib	20.1	50.1	Not reported	Not reported	Not reported
Cohort 1: Arm B2: Forimtamig 0.75 mg + Carfilzomib	44.8	61.5	Not reported	Not reported	Not reported
Cohort 1: Arm B3: Forimtamig 1.5 mg + Carfilzomib	124	11.5	Not reported	Not reported	Not reported

Cycle 4 Day 15

Analysis denominator · Participants

Group	Source count
Cohort 1: Arm B1: Forimtamig 0.3 mg + Carfilzomib	6
Cohort 1: Arm B2: Forimtamig 0.75 mg + Carfilzomib	5
Cohort 1: Arm B3: Forimtamig 1.5 mg + Carfilzomib	2

Values in nanograms per milliliter (ng/mL) · Interval/dispersion: Geometric Coefficient of Variation
Group	Value	Spread	Lower	Upper	Comment
Cohort 1: Arm B1: Forimtamig 0.3 mg + Carfilzomib	27.8	37.4	Not reported	Not reported	Not reported
Cohort 1: Arm B2: Forimtamig 0.75 mg + Carfilzomib	61.0	66.1	Not reported	Not reported	Not reported
Cohort 1: Arm B3: Forimtamig 1.5 mg + Carfilzomib	97.9	25.5	Not reported	Not reported	Not reported

Cycle 4 Day 22

Analysis denominator · Participants

Group	Source count
Cohort 1: Arm B1: Forimtamig 0.3 mg + Carfilzomib	6
Cohort 1: Arm B2: Forimtamig 0.75 mg + Carfilzomib	5
Cohort 1: Arm B3: Forimtamig 1.5 mg + Carfilzomib	3

Values in nanograms per milliliter (ng/mL) · Interval/dispersion: Geometric Coefficient of Variation
Group	Value	Spread	Lower	Upper	Comment
Cohort 1: Arm B1: Forimtamig 0.3 mg + Carfilzomib	25.6	46.4	Not reported	Not reported	Not reported
Cohort 1: Arm B2: Forimtamig 0.75 mg + Carfilzomib	60.7	83.6	Not reported	Not reported	Not reported
Cohort 1: Arm B3: Forimtamig 1.5 mg + Carfilzomib	175	14.5	Not reported	Not reported	Not reported

Cycle 5 Day 1

Analysis denominator · Participants

Group	Source count
Cohort 1: Arm B1: Forimtamig 0.3 mg + Carfilzomib	6
Cohort 1: Arm B2: Forimtamig 0.75 mg + Carfilzomib	4
Cohort 1: Arm B3: Forimtamig 1.5 mg + Carfilzomib	4

Values in nanograms per milliliter (ng/mL) · Interval/dispersion: Geometric Coefficient of Variation
Group	Value	Spread	Lower	Upper	Comment
Cohort 1: Arm B1: Forimtamig 0.3 mg + Carfilzomib	25.5	42.9	Not reported	Not reported	Not reported
Cohort 1: Arm B2: Forimtamig 0.75 mg + Carfilzomib	72.8	9.5	Not reported	Not reported	Not reported
Cohort 1: Arm B3: Forimtamig 1.5 mg + Carfilzomib	87.0	254.2	Not reported	Not reported	Not reported

Pre-dose Cycle 5 Day 4

Analysis denominator · Participants

Group	Source count
Cohort 1: Arm B1: Forimtamig 0.3 mg + Carfilzomib	6
Cohort 1: Arm B2: Forimtamig 0.75 mg + Carfilzomib	6
Cohort 1: Arm B3: Forimtamig 1.5 mg + Carfilzomib	3

Values in nanograms per milliliter (ng/mL) · Interval/dispersion: Geometric Coefficient of Variation
Group	Value	Spread	Lower	Upper	Comment
Cohort 1: Arm B1: Forimtamig 0.3 mg + Carfilzomib	19.8	25.1	Not reported	Not reported	Not reported
Cohort 1: Arm B2: Forimtamig 0.75 mg + Carfilzomib	32.5	61.2	Not reported	Not reported	Not reported
Cohort 1: Arm B3: Forimtamig 1.5 mg + Carfilzomib	39.2	221.2	Not reported	Not reported	Not reported

4hours Post-dose Cycle 5 Day 4

Analysis denominator · Participants

Group	Source count
Cohort 1: Arm B1: Forimtamig 0.3 mg + Carfilzomib	5
Cohort 1: Arm B2: Forimtamig 0.75 mg + Carfilzomib	5
Cohort 1: Arm B3: Forimtamig 1.5 mg + Carfilzomib	2

Values in nanograms per milliliter (ng/mL) · Interval/dispersion: Geometric Coefficient of Variation
Group	Value	Spread	Lower	Upper	Comment
Cohort 1: Arm B1: Forimtamig 0.3 mg + Carfilzomib	17.3	15.5	Not reported	Not reported	Not reported
Cohort 1: Arm B2: Forimtamig 0.75 mg + Carfilzomib	29.7	68.3	Not reported	Not reported	Not reported
Cohort 1: Arm B3: Forimtamig 1.5 mg + Carfilzomib	96.4	18.8	Not reported	Not reported	Not reported

Cycle 5 Day 8

Analysis denominator · Participants

Group	Source count
Cohort 1: Arm B1: Forimtamig 0.3 mg + Carfilzomib	6
Cohort 1: Arm B2: Forimtamig 0.75 mg + Carfilzomib	5
Cohort 1: Arm B3: Forimtamig 1.5 mg + Carfilzomib	2

Values in nanograms per milliliter (ng/mL) · Interval/dispersion: Geometric Coefficient of Variation
Group	Value	Spread	Lower	Upper	Comment
Cohort 1: Arm B1: Forimtamig 0.3 mg + Carfilzomib	19.8	28.4	Not reported	Not reported	Not reported
Cohort 1: Arm B2: Forimtamig 0.75 mg + Carfilzomib	36.3	40.4	Not reported	Not reported	Not reported
Cohort 1: Arm B3: Forimtamig 1.5 mg + Carfilzomib	34.0	492.5	Not reported	Not reported	Not reported

Cycle 5 Day 15

Analysis denominator · Participants

Group	Source count
Cohort 1: Arm B1: Forimtamig 0.3 mg + Carfilzomib	5
Cohort 1: Arm B2: Forimtamig 0.75 mg + Carfilzomib	6
Cohort 1: Arm B3: Forimtamig 1.5 mg + Carfilzomib	2

Values in nanograms per milliliter (ng/mL) · Interval/dispersion: Geometric Coefficient of Variation
Group	Value	Spread	Lower	Upper	Comment
Cohort 1: Arm B1: Forimtamig 0.3 mg + Carfilzomib	23.1	25.8	Not reported	Not reported	Not reported
Cohort 1: Arm B2: Forimtamig 0.75 mg + Carfilzomib	38.9	83.2	Not reported	Not reported	Not reported
Cohort 1: Arm B3: Forimtamig 1.5 mg + Carfilzomib	145	4.9	Not reported	Not reported	Not reported

Cycle 6 Day 1

Analysis denominator · Participants

Group	Source count
Cohort 1: Arm B1: Forimtamig 0.3 mg + Carfilzomib	6
Cohort 1: Arm B2: Forimtamig 0.75 mg + Carfilzomib	4
Cohort 1: Arm B3: Forimtamig 1.5 mg + Carfilzomib	1

Values in nanograms per milliliter (ng/mL) · Interval/dispersion: Geometric Coefficient of Variation
Group	Value	Spread	Lower	Upper	Comment
Cohort 1: Arm B1: Forimtamig 0.3 mg + Carfilzomib	28.0	34.5	Not reported	Not reported	Not reported
Cohort 1: Arm B2: Forimtamig 0.75 mg + Carfilzomib	41.3	104.3	Not reported	Not reported	Not reported
Cohort 1: Arm B3: Forimtamig 1.5 mg + Carfilzomib	103	NA	Not reported	Not reported	Geometric coefficient of variation was not estimable for 1 participant.

Cycle 6 Day 4

Analysis denominator · Participants

Group	Source count
Cohort 1: Arm B1: Forimtamig 0.3 mg + Carfilzomib	6
Cohort 1: Arm B2: Forimtamig 0.75 mg + Carfilzomib	6
Cohort 1: Arm B3: Forimtamig 1.5 mg + Carfilzomib	3

Values in nanograms per milliliter (ng/mL) · Interval/dispersion: Geometric Coefficient of Variation
Group	Value	Spread	Lower	Upper	Comment
Cohort 1: Arm B1: Forimtamig 0.3 mg + Carfilzomib	26.4	34.0	Not reported	Not reported	Not reported
Cohort 1: Arm B2: Forimtamig 0.75 mg + Carfilzomib	44.7	69.9	Not reported	Not reported	Not reported
Cohort 1: Arm B3: Forimtamig 1.5 mg + Carfilzomib	66.3	404.6	Not reported	Not reported	Not reported

Cycle 6 Day 8

Analysis denominator · Participants

Group	Source count
Cohort 1: Arm B1: Forimtamig 0.3 mg + Carfilzomib	6
Cohort 1: Arm B2: Forimtamig 0.75 mg + Carfilzomib	5
Cohort 1: Arm B3: Forimtamig 1.5 mg + Carfilzomib	3

Values in nanograms per milliliter (ng/mL) · Interval/dispersion: Geometric Coefficient of Variation
Group	Value	Spread	Lower	Upper	Comment
Cohort 1: Arm B1: Forimtamig 0.3 mg + Carfilzomib	19.0	31.6	Not reported	Not reported	Not reported
Cohort 1: Arm B2: Forimtamig 0.75 mg + Carfilzomib	NA	NA	Not reported	Not reported	Geometric mean and geometric coefficient of variation were not estimable as samples were BLQ.
Cohort 1: Arm B3: Forimtamig 1.5 mg + Carfilzomib	41.7	113.7	Not reported	Not reported	Not reported

Cycle 6 Day 15

Analysis denominator · Participants

Group	Source count
Cohort 1: Arm B1: Forimtamig 0.3 mg + Carfilzomib	6
Cohort 1: Arm B2: Forimtamig 0.75 mg + Carfilzomib	5
Cohort 1: Arm B3: Forimtamig 1.5 mg + Carfilzomib	3

Values in nanograms per milliliter (ng/mL) · Interval/dispersion: Geometric Coefficient of Variation
Group	Value	Spread	Lower	Upper	Comment
Cohort 1: Arm B1: Forimtamig 0.3 mg + Carfilzomib	18.0	58.8	Not reported	Not reported	Not reported
Cohort 1: Arm B2: Forimtamig 0.75 mg + Carfilzomib	20.2	262.3	Not reported	Not reported	Not reported
Cohort 1: Arm B3: Forimtamig 1.5 mg + Carfilzomib	62.1	133.8	Not reported	Not reported	Not reported

Cycle 7 Day 1

Analysis denominator · Participants

Group	Source count
Cohort 1: Arm B1: Forimtamig 0.3 mg + Carfilzomib	5
Cohort 1: Arm B2: Forimtamig 0.75 mg + Carfilzomib	3
Cohort 1: Arm B3: Forimtamig 1.5 mg + Carfilzomib	1

Values in nanograms per milliliter (ng/mL) · Interval/dispersion: Geometric Coefficient of Variation
Group	Value	Spread	Lower	Upper	Comment
Cohort 1: Arm B1: Forimtamig 0.3 mg + Carfilzomib	27.6	57.8	Not reported	Not reported	Not reported
Cohort 1: Arm B2: Forimtamig 0.75 mg + Carfilzomib	10.3	143751.7	Not reported	Not reported	Not reported
Cohort 1: Arm B3: Forimtamig 1.5 mg + Carfilzomib	140	NA	Not reported	Not reported	Geometric coefficient of variation was not estimable for 1 participant.

Cycle 7 Day 4

Analysis denominator · Participants

Group	Source count
Cohort 1: Arm B1: Forimtamig 0.3 mg + Carfilzomib	6
Cohort 1: Arm B2: Forimtamig 0.75 mg + Carfilzomib	3
Cohort 1: Arm B3: Forimtamig 1.5 mg + Carfilzomib	3

Values in nanograms per milliliter (ng/mL) · Interval/dispersion: Geometric Coefficient of Variation
Group	Value	Spread	Lower	Upper	Comment
Cohort 1: Arm B1: Forimtamig 0.3 mg + Carfilzomib	23.9	67.1	Not reported	Not reported	Not reported
Cohort 1: Arm B2: Forimtamig 0.75 mg + Carfilzomib	73.5	19.5	Not reported	Not reported	Not reported
Cohort 1: Arm B3: Forimtamig 1.5 mg + Carfilzomib	88.7	104.1	Not reported	Not reported	Not reported

Cycle 7 Day 8

Analysis denominator · Participants

Group	Source count
Cohort 1: Arm B1: Forimtamig 0.3 mg + Carfilzomib	4
Cohort 1: Arm B2: Forimtamig 0.75 mg + Carfilzomib	4
Cohort 1: Arm B3: Forimtamig 1.5 mg + Carfilzomib	3

Values in nanograms per milliliter (ng/mL) · Interval/dispersion: Geometric Coefficient of Variation
Group	Value	Spread	Lower	Upper	Comment
Cohort 1: Arm B1: Forimtamig 0.3 mg + Carfilzomib	12.4	58.4	Not reported	Not reported	Not reported
Cohort 1: Arm B2: Forimtamig 0.75 mg + Carfilzomib	24.4	158.9	Not reported	Not reported	Not reported
Cohort 1: Arm B3: Forimtamig 1.5 mg + Carfilzomib	76.4	50.3	Not reported	Not reported	Not reported

Cycle 7 Day 15

Analysis denominator · Participants

Group	Source count
Cohort 1: Arm B1: Forimtamig 0.3 mg + Carfilzomib	4
Cohort 1: Arm B2: Forimtamig 0.75 mg + Carfilzomib	1
Cohort 1: Arm B3: Forimtamig 1.5 mg + Carfilzomib	3

Values in nanograms per milliliter (ng/mL) · Interval/dispersion: Geometric Coefficient of Variation
Group	Value	Spread	Lower	Upper	Comment
Cohort 1: Arm B1: Forimtamig 0.3 mg + Carfilzomib	6.52	265.7	Not reported	Not reported	Not reported
Cohort 1: Arm B2: Forimtamig 0.75 mg + Carfilzomib	24.9	NA	Not reported	Not reported	Geometric coefficient of variation was not estimable for 1 participant.
Cohort 1: Arm B3: Forimtamig 1.5 mg + Carfilzomib	98.2	52.4	Not reported	Not reported	Not reported

Cycle 8 Day 1

Analysis denominator · Participants

Group	Source count
Cohort 1: Arm B1: Forimtamig 0.3 mg + Carfilzomib	3
Cohort 1: Arm B2: Forimtamig 0.75 mg + Carfilzomib	4
Cohort 1: Arm B3: Forimtamig 1.5 mg + Carfilzomib	1

Values in nanograms per milliliter (ng/mL) · Interval/dispersion: Geometric Coefficient of Variation
Group	Value	Spread	Lower	Upper	Comment
Cohort 1: Arm B1: Forimtamig 0.3 mg + Carfilzomib	20.0	25.8	Not reported	Not reported	Not reported
Cohort 1: Arm B2: Forimtamig 0.75 mg + Carfilzomib	52.8	74.3	Not reported	Not reported	Not reported
Cohort 1: Arm B3: Forimtamig 1.5 mg + Carfilzomib	171	NA	Not reported	Not reported	Geometric coefficient of variation was not estimable for 1 participant.

Cycle 8 Day 4

Analysis denominator · Participants

Group	Source count
Cohort 1: Arm B1: Forimtamig 0.3 mg + Carfilzomib	4
Cohort 1: Arm B2: Forimtamig 0.75 mg + Carfilzomib	2
Cohort 1: Arm B3: Forimtamig 1.5 mg + Carfilzomib	2

Values in nanograms per milliliter (ng/mL) · Interval/dispersion: Geometric Coefficient of Variation
Group	Value	Spread	Lower	Upper	Comment
Cohort 1: Arm B1: Forimtamig 0.3 mg + Carfilzomib	20.2	13.0	Not reported	Not reported	Not reported
Cohort 1: Arm B2: Forimtamig 0.75 mg + Carfilzomib	53.6	47.4	Not reported	Not reported	Not reported
Cohort 1: Arm B3: Forimtamig 1.5 mg + Carfilzomib	91.7	60.4	Not reported	Not reported	Not reported

Cycle 8 Day 8

Analysis denominator · Participants

Group	Source count
Cohort 1: Arm B1: Forimtamig 0.3 mg + Carfilzomib	3
Cohort 1: Arm B2: Forimtamig 0.75 mg + Carfilzomib	2
Cohort 1: Arm B3: Forimtamig 1.5 mg + Carfilzomib	2

Values in nanograms per milliliter (ng/mL) · Interval/dispersion: Geometric Coefficient of Variation
Group	Value	Spread	Lower	Upper	Comment
Cohort 1: Arm B1: Forimtamig 0.3 mg + Carfilzomib	12.1	78.4	Not reported	Not reported	Not reported
Cohort 1: Arm B2: Forimtamig 0.75 mg + Carfilzomib	21.3	24.8	Not reported	Not reported	Not reported
Cohort 1: Arm B3: Forimtamig 1.5 mg + Carfilzomib	78.6	45.8	Not reported	Not reported	Not reported

Cycle 8 Day 15

Analysis denominator · Participants

Group	Source count
Cohort 1: Arm B1: Forimtamig 0.3 mg + Carfilzomib	2
Cohort 1: Arm B2: Forimtamig 0.75 mg + Carfilzomib	2
Cohort 1: Arm B3: Forimtamig 1.5 mg + Carfilzomib	1

Values in nanograms per milliliter (ng/mL) · Interval/dispersion: Geometric Coefficient of Variation
Group	Value	Spread	Lower	Upper	Comment
Cohort 1: Arm B1: Forimtamig 0.3 mg + Carfilzomib	16.4	3.5	Not reported	Not reported	Not reported
Cohort 1: Arm B2: Forimtamig 0.75 mg + Carfilzomib	21.6	148.2	Not reported	Not reported	Not reported
Cohort 1: Arm B3: Forimtamig 1.5 mg + Carfilzomib	153	NA	Not reported	Not reported	Geometric coefficient of variation was not estimable for 1 participant.

Cycle 9 Day 1

Analysis denominator · Participants

Group	Source count
Cohort 1: Arm B1: Forimtamig 0.3 mg + Carfilzomib	2
Cohort 1: Arm B2: Forimtamig 0.75 mg + Carfilzomib	1
Cohort 1: Arm B3: Forimtamig 1.5 mg + Carfilzomib	2

Values in nanograms per milliliter (ng/mL) · Interval/dispersion: Geometric Coefficient of Variation
Group	Value	Spread	Lower	Upper	Comment
Cohort 1: Arm B1: Forimtamig 0.3 mg + Carfilzomib	24.0	52.1	Not reported	Not reported	Not reported
Cohort 1: Arm B2: Forimtamig 0.75 mg + Carfilzomib	71.0	NA	Not reported	Not reported	Geometric coefficient of variation was not estimable for 1 participant.
Cohort 1: Arm B3: Forimtamig 1.5 mg + Carfilzomib	136	19.9	Not reported	Not reported	Not reported

Cycle 9 Day 4

Analysis denominator · Participants

Group	Source count
Cohort 1: Arm B1: Forimtamig 0.3 mg + Carfilzomib	2
Cohort 1: Arm B2: Forimtamig 0.75 mg + Carfilzomib	1
Cohort 1: Arm B3: Forimtamig 1.5 mg + Carfilzomib	2

Values in nanograms per milliliter (ng/mL) · Interval/dispersion: Geometric Coefficient of Variation
Group	Value	Spread	Lower	Upper	Comment
Cohort 1: Arm B1: Forimtamig 0.3 mg + Carfilzomib	22.9	33.1	Not reported	Not reported	Not reported
Cohort 1: Arm B2: Forimtamig 0.75 mg + Carfilzomib	65.4	NA	Not reported	Not reported	Geometric coefficient of variation was not estimable for 1 participant.
Cohort 1: Arm B3: Forimtamig 1.5 mg + Carfilzomib	109	23.4	Not reported	Not reported	Not reported

Cycle 9 Day 8

Analysis denominator · Participants

Group	Source count
Cohort 1: Arm B1: Forimtamig 0.3 mg + Carfilzomib	0
Cohort 1: Arm B2: Forimtamig 0.75 mg + Carfilzomib	1
Cohort 1: Arm B3: Forimtamig 1.5 mg + Carfilzomib	1

Values in nanograms per milliliter (ng/mL) · Interval/dispersion: Geometric Coefficient of Variation
Group	Value	Spread	Lower	Upper	Comment
Cohort 1: Arm B2: Forimtamig 0.75 mg + Carfilzomib	32.3	NA	Not reported	Not reported	Geometric coefficient of variation was not estimable for 1 participant.
Cohort 1: Arm B3: Forimtamig 1.5 mg + Carfilzomib	121	NA	Not reported	Not reported	Geometric coefficient of variation was not estimable for 1 participant.

Cycle 9 Day 15

Analysis denominator · Participants

Group	Source count
Cohort 1: Arm B1: Forimtamig 0.3 mg + Carfilzomib	2
Cohort 1: Arm B2: Forimtamig 0.75 mg + Carfilzomib	1
Cohort 1: Arm B3: Forimtamig 1.5 mg + Carfilzomib	1

Values in nanograms per milliliter (ng/mL) · Interval/dispersion: Geometric Coefficient of Variation
Group	Value	Spread	Lower	Upper	Comment
Cohort 1: Arm B1: Forimtamig 0.3 mg + Carfilzomib	31.6	17.8	Not reported	Not reported	Not reported
Cohort 1: Arm B2: Forimtamig 0.75 mg + Carfilzomib	45.7	NA	Not reported	Not reported	Geometric coefficient of variation was not estimable for 1 participant.
Cohort 1: Arm B3: Forimtamig 1.5 mg + Carfilzomib	195	NA	Not reported	Not reported	Geometric coefficient of variation was not estimable for 1 participant.

Cycle 10 Day 1

Analysis denominator · Participants

Group	Source count
Cohort 1: Arm B1: Forimtamig 0.3 mg + Carfilzomib	2
Cohort 1: Arm B2: Forimtamig 0.75 mg + Carfilzomib	1
Cohort 1: Arm B3: Forimtamig 1.5 mg + Carfilzomib	1

Values in nanograms per milliliter (ng/mL) · Interval/dispersion: Geometric Coefficient of Variation
Group	Value	Spread	Lower	Upper	Comment
Cohort 1: Arm B1: Forimtamig 0.3 mg + Carfilzomib	19.4	4.7	Not reported	Not reported	Not reported
Cohort 1: Arm B2: Forimtamig 0.75 mg + Carfilzomib	10.8	NA	Not reported	Not reported	Geometric coefficient of variation was not estimable for 1 participant.
Cohort 1: Arm B3: Forimtamig 1.5 mg + Carfilzomib	146	NA	Not reported	Not reported	Geometric coefficient of variation was not estimable for 1 participant.

Cycle 10 Day 4

Analysis denominator · Participants

Group	Source count
Cohort 1: Arm B1: Forimtamig 0.3 mg + Carfilzomib	1
Cohort 1: Arm B2: Forimtamig 0.75 mg + Carfilzomib	1
Cohort 1: Arm B3: Forimtamig 1.5 mg + Carfilzomib	0

Values in nanograms per milliliter (ng/mL) · Interval/dispersion: Geometric Coefficient of Variation
Group	Value	Spread	Lower	Upper	Comment
Cohort 1: Arm B1: Forimtamig 0.3 mg + Carfilzomib	9.30	NA	Not reported	Not reported	Geometric coefficient of variation was not estimable for 1 participant.
Cohort 1: Arm B2: Forimtamig 0.75 mg + Carfilzomib	17.8	NA	Not reported	Not reported	Geometric coefficient of variation was not estimable for 1 participant.

Cycle 10 Day 8

Analysis denominator · Participants

Group	Source count
Cohort 1: Arm B1: Forimtamig 0.3 mg + Carfilzomib	1
Cohort 1: Arm B2: Forimtamig 0.75 mg + Carfilzomib	1
Cohort 1: Arm B3: Forimtamig 1.5 mg + Carfilzomib	1

Values in nanograms per milliliter (ng/mL) · Interval/dispersion: Geometric Coefficient of Variation
Group	Value	Spread	Lower	Upper	Comment
Cohort 1: Arm B1: Forimtamig 0.3 mg + Carfilzomib	41.4	NA	Not reported	Not reported	Geometric coefficient of variation was not estimable for 1 participant.
Cohort 1: Arm B2: Forimtamig 0.75 mg + Carfilzomib	30.8	NA	Not reported	Not reported	Geometric coefficient of variation was not estimable for 1 participant.
Cohort 1: Arm B3: Forimtamig 1.5 mg + Carfilzomib	135	NA	Not reported	Not reported	Geometric coefficient of variation was not estimable for 1 participant.

Complete source fields

classes

categories
measurements
comment
Geometric mean and geometric coefficient of variation were not estimable as samples were below the limit of quantification (BLQ).
group Id
OG000
spread
NA
value
NA
comment
Geometric mean and geometric coefficient of variation were not estimable as samples were BLQ.
group Id
OG001
spread
NA
value
NA
comment
Geometric mean and geometric coefficient of variation were not estimable as samples were BLQ.
group Id
OG002
spread
NA
value
NA
denoms
counts
group Id
OG000
value
7
group Id
OG001
value
2
group Id
OG002
value
4
units
Participants
title
Pre-dose Cycle 1 Day 1
categories
measurements
comment
Geometric mean and geometric coefficient of variation were not estimable as samples were BLQ.
group Id
OG000
spread
NA
value
NA
comment
Geometric mean and geometric coefficient of variation were not estimable as samples were BLQ.
group Id
OG001
spread
NA
value
NA
comment
Geometric mean and geometric coefficient of variation were not estimable as samples were BLQ.
group Id
OG002
spread
NA
value
NA
denoms
counts
group Id
OG000
value
7
group Id
OG001
value
2
group Id
OG002
value
4
units
Participants
title
4hours Post-dose Cycle 1 Day 1
categories
measurements
group Id
OG000
spread
109.6
value
6.21
group Id
OG001
spread
94.8
value
2.76
group Id
OG002
spread
250.5
value
2.44
denoms
counts
group Id
OG000
value
6
group Id
OG001
value
5
group Id
OG002
value
6
units
Participants
title
Cycle 1 Day 2
categories
measurements
group Id
OG000
spread
50.8
value
6.55
group Id
OG001
spread
115.3
value
3.69
group Id
OG002
spread
384.1
value
2.64
denoms
counts
group Id
OG000
value
6
group Id
OG001
value
6
group Id
OG002
value
6
units
Participants
title
Pre-dose Cycle 1 Day 4
categories
measurements
group Id
OG000
spread
52.4
value
7.26
group Id
OG001
spread
69.9
value
6.99
comment
Geometric mean and geometric coefficient of variation were not estimable as samples were BLQ.
group Id
OG002
spread
NA
value
NA
denoms
counts
group Id
OG000
value
5
group Id
OG001
value
6
group Id
OG002
value
6
units
Participants
title
4 hours Post-dose Cycle 1 Day 4
categories
measurements
group Id
OG000
spread
44.7
value
10.3
group Id
OG001
spread
51.6
value
21.4
group Id
OG002
spread
434.0
value
25.4
denoms
counts
group Id
OG000
value
5
group Id
OG001
value
6
group Id
OG002
value
6
units
Participants
title
Cycle 1 Day 8
categories
measurements
group Id
OG000
spread
33.9
value
13.0
group Id
OG001
spread
589.1
value
14.9
group Id
OG002
spread
268.2
value
39.3
denoms
counts
group Id
OG000
value
4
group Id
OG001
value
6
group Id
OG002
value
6
units
Participants
title
Cycle 1 Day 9
categories
measurements
comment
Geometric mean and geometric coefficient of variation were not estimable as samples were BLQ.
group Id
OG000
spread
NA
value
NA
comment
Geometric mean and geometric coefficient of variation were not estimable as samples were BLQ.
group Id
OG001
spread
NA
value
NA
comment
Geometric mean and geometric coefficient of variation were not estimable as samples were BLQ.
group Id
OG002
spread
NA
value
NA
denoms
counts
group Id
OG000
value
7
group Id
OG001
value
2
group Id
OG002
value
4
units
Participants
title
Cycle 1 Day 11
categories
measurements
comment
Geometric mean and geometric coefficient of variation were not estimable as samples were BLQ.
group Id
OG000
spread
NA
value
NA
comment
Geometric mean and geometric coefficient of variation were not estimable as samples were BLQ.
group Id
OG001
spread
NA
value
NA
group Id
OG002
spread
100.8
value
0.367
denoms
counts
group Id
OG000
value
7
group Id
OG001
value
2
group Id
OG002
value
4
units
Participants
title
Cycle 1 Day 15
categories
measurements
group Id
OG000
spread
13.8
value
17.0
comment
Geometric coefficient of variation was not estimable for 1 participant.
group Id
OG001
spread
NA
value
18.9
comment
Geometric coefficient of variation was not estimable for 1 participant.
group Id
OG002
spread
NA
value
147
denoms
counts
group Id
OG000
value
2
group Id
OG001
value
1
group Id
OG002
value
1
units
Participants
title
Cycle 1 Day 16
categories
measurements
group Id
OG000
spread
0.6
value
23.2
comment
Geometric coefficient of variation was not estimable for 1 participant.
group Id
OG001
spread
NA
value
27.7
comment
Geometric coefficient of variation was not estimable for 1 participant.
group Id
OG002
spread
NA
value
178
denoms
counts
group Id
OG000
value
2
group Id
OG001
value
1
group Id
OG002
value
1
units
Participants
title
Cycle 1 Day 18
categories
measurements
group Id
OG000
spread
121.8
value
0.712
comment
Geometric mean and geometric coefficient of variation were not estimable as samples were BLQ.
group Id
OG001
spread
NA
value
NA
comment
Geometric mean and geometric coefficient of variation were not estimable as samples were BLQ.
group Id
OG002
spread
NA
value
NA
denoms
counts
group Id
OG000
value
6
group Id
OG001
value
6
group Id
OG002
value
6
units
Participants
title
Pre-dose Cycle 2 Day 1

denoms

counts
group Id
OG000
value
7
group Id
OG001
value
6
group Id
OG002
value
6
units
Participants

dispersion Type

Geometric Coefficient of Variation

groups

description
Participants received step-up doses of forimtamig 0.03 mg on Cycle 1 Day 1, 0.15 mg on Cycle 1 Day 8, and the target dose of 0.3 mg on Cycle 1 Day 15 and on Days 1 and 15 of each subsequent cycle, administered as a SC injection. Participants also received carfilzomib, 20 mg/m\^2 on Cycle 2 Day 1 and 56 mg/m\^2 on Cycle 2 Days 8 and 15, and from Cycle 3 onwards on Days 1, 8, and 15, administered as an IV infusion (1 cycle = 28 days).
id
OG000
title
Cohort 1: Arm B1: Forimtamig 0.3 mg + Carfilzomib
description
Participants received step-up doses of forimtamig, 0.03 mg on Cycle 1 Day 1, 0.15 mg on Cycle 1 Day 8, and the target dose of 0.75 mg on Cycle 1 Day 15 and on Days 1 and 15 of each subsequent cycle, administered as a SC injection. Participants also received carfilzomib 20 mg/m\^2 on Cycle 2 Day 1 and 56 mg/m\^2 on Cycle 2 Days 8 and 15, and from Cycle 3 onwards on Days 1, 8, and 15, administered as an IV infusion (1 cycle = 28 days).
id
OG001
title
Cohort 1: Arm B2: Forimtamig 0.75 mg + Carfilzomib
description
Participants received step-up doses of forimtamig, 0.03 mg on Cycle 1 Day 1, 0.15 mg on Cycle 1 Day 8, and the target dose of 1.5 mg on Cycle 1 Day 15 and on Days 1 and 15 of each subsequent cycle, administered as a SC injection. Participants also received carfilzomib, 20 mg/m\^2 on Cycle 2 Day 1 and 56 mg/m\^2 on Cycle 2 Days 8 and 15, and from Cycle 3 onwards on Days 1, 8, and 15, administered as an IV infusion (1 cycle = 28 days).
id
OG002
title
Cohort 1: Arm B3: Forimtamig 1.5 mg + Carfilzomib

param Type

GEOMETRIC_MEAN

population Description

Pharmacokinetic (PK)-evaluable population included all participants in the safety population who had PK data from at least one post-dose sample. Overall number analyzed is the number of participants with data available for analysis. Number analyzed is the number of participants with data available for analysis at the specified time points.

reporting Status

POSTED

time Frame

Pre-dose on Day (D)1 of Cycle (C)1,2&4, D4 of C1&5, D2C3; 4hours post-dose on D1,4 of C1, D2C3, D1C4, D4C5; D2,8,9,11,15,16&18 of C1; D2,8,15,22 of C2&4; D1,4,8,15,22 of C3; D1,8,15 of C5; D1,4,8,15 of C6,7,8&9; D1,4,8 of C10

title

Serum Concentrations of Forimtamig at the Specified Timepoints

type

SECONDARY

unit Of Measure

nanograms per milliliter (ng/mL)

Download exact source JSON → · Snapshot ctgov-results-d643ffaf417bcef6d45eb5e0

Preserved source evidence · Not medical advice